EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study

Xinyi Hong, Shanhu Qiu, Xia Wu, Sizhen Chen, Xiaoxiang Chen iD, Bei Zhang, Aiqin He, Yun Xu, Jianqing Wang, Yingchun Gao, Xizhong Xu, Li Sun und 10 weitere

Drug Design, Development and Therapy · 2023

DOI: 10.2147/dddt.s408304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2023. Verfasst von Xinyi Hong und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, People's Republic of C…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsOvarian NeoplasmsHumansFemaleIndolesQuinolines

Stichwörter der Autor:innen

angiogenesis inhibitorsmolecular-targeting therapyreal-world study

Substanzen

IndolesanlotinibQuinolines

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, People's Republic of China.
  • Department of General Practice, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, People's Republic of China.
  • Department of Gynecological Oncology, Tumor Hospital Affiliated to Nantong University, Nantong, Jiangsu, People's Republic of China.
  • Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing, People's Republic of China.
  • Department of Gynecological Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
  • Department of Obstetrics and Gynecology, Xuzhou Central Hospital, Xuzhou, People's Republic of China.

ORCID-Profile: Xiaoxiang Chen, Haiyan Liu, Bingwei Chen, Yang Shen

Zitieren

APA

Hong, X., Qiu, S., Wu, X., Chen, S., Chen, X., Zhang, B., He, A., Xu, Y., Wang, J., Gao, Y., Xu, X., Sun, L., Zhang, Y., Xiang, L., Zhou, J., Guan, Q., Zhu, Y., Liu, H., Xu, H., …, & Shen, Y. (2023). Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s408304

Vancouver

Hong X, Qiu S, Wu X, Chen S, Chen X, Zhang B, et al. Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study. Drug Design, Development and Therapy. 2023. doi:10.2147/dddt.s408304

BibTeX
@article{Hong2023,
  author = {Hong, Xinyi and Qiu, Shanhu and Wu, Xia and Chen, Sizhen and Chen, Xiaoxiang and Zhang, Bei and He, Aiqin and Xu, Yun and Wang, Jianqing and Gao, Yingchun and Xu, Xizhong and Sun, Li and Zhang, Yang and Xiang, Libing and Zhou, Jundong and Guan, Qun and Zhu, Yanling and Liu, Haiyan and Xu, Hao and Zhou, Ying and Chen, Bingwei and Shen, Yang},
  title = {Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study},
  journal = {Drug Design, Development and Therapy},
  year = {2023},
  doi = {10.2147/dddt.s408304}
}
Kostenlos starten →